Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Additional Outcomes

  • Unrelated vs. Sibling Donor Outcomes
  • Older Patient Outcomes
  • Timing Impact on Outcomes
Research Spotlight
  • HLA matching in the setting of PTCy improves outcomes in related and unrelated donor HCT

    July 2022

  • Abatacept can reduce racial disparities by mitigating the impact of mismatching in unrelated donor HCT

    January 2022

  • Less HLA mismatching may provide better outcomes over haploidentical donor HCT in the setting of PTCy

    January 2022

  • Transplant Indications and Outcomes
  • Additional Outcomes
  • Unrelated vs. Sibling Donor Outcomes
  • Email
  • Print This Page

Related Resources

  • HCT Cell Sources
  • All Outcomes and Statistics Slides

    Patient Resources

    • Transplant Outcomes and Treatment Decisions
    • Transplant Basics Booklet
    • Transplant Basics Videos

      Unrelated vs. Sibling Donor Outcomes

      Due to several clinical advances, such as more precise HLA typing and advances in patient care, unrelated donor transplant outcomes are now comparable to related donor transplant outcomes in many patient populations. [1,2,3,4,5]

      The continued improvement in outcomes has led to an increase in the number of unrelated donor transplants. In 2022, Be The Match® facilitated 6,714 transplants.

      Advances

      Figure 2 shows landmark one-year survival for a rolling cohort of patients consisting of the specified three-year periods. [6] The data show that one-year transplant outcomes for U.S. patients (all diseases, ages and graft types) with unrelated donors have improved 10 percentage points between transplant periods ending in 2005 and in 2010.

      Figure 2. One-Year Survival, NMDP/Be The Match Transplants

      Improved One-Year Survival, Unrelated Donor HCT

      Download Slide: Improved One-Year Survival, Unrelated Donor Transplants

      Advances in treating post-transplant complications and more precise HLA matching have contributed to the improvements in survival. [7,8,9] Unrelated donor transplant outcomes are now comparable to related donor transplant outcomes in several patient populations. [1,2,3,4,5]

      Due to the increased size and ethnic diversity of the Be The Match Registry® and other donor registries, most patients lacking a suitably matched related donor will be able to find an alternative donor and proceed to transplant.

      References

      1. Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant. 2007; 13(12): 1499-1507. Access
      2. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(8): 1196-1204. Access
      3. Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908-3916. Access
      4. Robin M, Porcher R, Adès L, et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant. 2013; 48(10): 1296-1301. Access
      5. Zhang MJ, Davies SM, Camitta BM, et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012; 18(8): 1204-1210. Access
      6. CIBMTR Analysis of NMDP Facilitated Transplants 2013. Unadjusted one-year survival of unrelated transplant recipients after first allogeneic transplantation at U.S. transplant centers.
      7. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. Access
      8. Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008; 14(9, Suppl. 3): 37-44. Access
      9. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007; 69(Suppl. 1): 25-30. Access
      • Email
      • Print This Page

      Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

      Transplant Indications and Outcomes

      • HLA Today
      • Disease-Specific Indications and Outcomes
      • Additional Outcomes
      • Eligibility
      • Referral Timing Guidelines
      • Order Kits
      • HLA Typing for Family Members

      Transplant Therapy and Donor Matching

      • Cell Sources
      • HLA Typing and Matching
      • Donor or Cord Blood Search Process
      • Jason Carter Clinical Trials Program

      Resources

      • Patient Resources
      • Financial Resources
      • Obstetrician Resources
      • Technique Videos
      • Umbilical Cord Blood Collection Training for Public Donation
      • Local Provider Partnership Program

      Contact Us

      About Us

      Our Websites

      bethematch.org
      BeTheMatch.org Information and support for patients, donors and supporters of our mission.
      BeTheMatchBioTherapies.com
      BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
      CIBMTR.org
      CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
      National Marrow Donor Program —
      Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
      Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright